Payment overview · 2025
General Payments
$67,635.97
100 reported records · 7 companies
Healthcare provider profile · identity verified
Jeremy D Coplan, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychosomatic Medicine · MANHASSET, NY · NPI 1346468600
Verified facts
What the public records show
CMS Open Payments records show Jeremy D Coplan, MD received $67,635.97 in general payments during 2025 across 100 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 62.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Lybalvi, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Auvelity by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Caplyta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42,522.14 | 62.9% | 36 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $12,536.82 | 18.5% | 32 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $5,546.44 | 8.2% | 10 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $3,880.53 | 5.7% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $2,934.07 | 4.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $174.25 | 0.3% | 8 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $41.72 | 0.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,750.00 | 12 |
| Consulting Fee | $17,878.50 | 5 |
| Travel and Lodging | $4,796.99 | 12 |
| Food and Beverage | $3,370.21 | 69 |
| Honoraria | $2,813.00 | 1 |
| Education | $27.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42,522.14 | 36 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $5,546.44 | 10 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $3,880.53 | 10 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $2,934.07 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $1,595.82 | 29 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $157.17 | 5 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $17.08 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $17.08 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 47 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
92 | 13 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lamotrigine | Lamotrigine | 598 | 86 |
| Clonazepam | Clonazepam | 253 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 223 | 37 |
| Bupropion Xl | Bupropion Hcl | 205 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 205 | 34 |
| Aripiprazole | Aripiprazole | 152 | 32 |
| Alprazolam | Alprazolam | 145 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 137 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 129 | 17 |
| Lurasidone Hcl | Lurasidone Hcl | 124 | 14 |
| Trazodone Hcl | Trazodone Hcl | 123 | 30 |
| Vyvanse | Lisdexamfetamine Dimesylate | 105 | 14 |
| Lorazepam | Lorazepam | 96 | 18 |
| Sertraline Hcl | Sertraline Hcl | 93 | 18 |
| Vraylar | Cariprazine Hcl | 92 | 13 |
| Gabapentin | Gabapentin | 91 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 14 |
| Olanzapine | Olanzapine | 70 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 64 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 58 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | suppressed |
| Diazepam | Diazepam | 50 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 47 | 16 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 44 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Clozapine | Clozapine | 35 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 31 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 31 | suppressed |
| Zoloft | Sertraline Hcl | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Caplyta | Lumateperone Tosylate | 26 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 23 | suppressed |
| Klonopin | Clonazepam | 22 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Austedo Xr | Deutetrabenazine | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Perphenazine | Perphenazine | 14 | suppressed |
| Cymbalta | Duloxetine Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $67,635.97 · 100 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, Auvelity, Azstarys, CAPLYTA, COBENFY, LYBALVI, REXULTI, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error